SpringWorks Therapeutics ... (SWTX)
56.19
-1.24 (-2.16%)
At close: Feb 18, 2025, 3:59 PM
56.72
0.94%
After-hours: Feb 18, 2025, 07:59 PM EST
undefined% (undefined)
| Bid | 56.69 |
| Market Cap | 4.18B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.89 |
| PE Ratio (ttm) | -14.44 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 57.59 |
| Volume | 3,006,798 |
| Avg. Volume (20D) | 1,823,844 |
| Open | 55.96 |
| Previous Close | 57.43 |
| Day's Range | 55.02 - 56.97 |
| 52-Week Range | 28.21 - 60.00 |
| Beta | undefined |
About SWTX
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2019
Employees 305
Stock Exchange NASDAQ
Ticker Symbol SWTX
Website https://www.springworkstx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is $71, which is an increase of 26.36% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
SpringWorks Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+34.06%
SpringWorks Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
1 month ago
-13.93%
SpringWorks Therapeutics shares are trading lower following Q4 and FY24 financial results
